Sixty percent of the regenerative medicine
market focuses on cell therapy; with its primary focus on stem cell therapy.
Globally, there are over companies focused on regenerative medicine
have the ability to restore the lost functionality of tissues or organs, unlike conventional medicines, which are palliative.
To establish and maintain technology platform involving regenerative medicine
and cell therapy taking advantage of multi-functional characteristics of cells in order to realize higher efficacy of treatment that cannot be achieved by existing therapy.
While the principles of regenerative medicine
are easy to explain and the possible benefits even easier to appraise, relatively few products have made it into clinical trials, and even fewer into therapy.
Thayer says he will seek out a place on the board of directors for the Regenerative Medicine
Research Institute and Tissue Bank.
The report provides a detailed understanding and analysis of how and why companies enter regenerative medicine
and stem cells partnering deals.
has also been an area of interest for major pharma companies, many of which have set up their own R & D units or have acquired stakes / invested in regenerative medicine
Japan s only company dealing with regenerative medical products, to promote the project for practical application of regenerative medicine
in China and Thailand , one of the projects adopted under the Ministry of Economy, Trade and Industry s feasibility research on the overseas deployment of Japanese medical devices and services .
However, these challenges will be overcome by the maturing market, investment from pharmaceutical companies and the creation of regenerative medicine
Details of the achievement will be presented at the 5th Annual Congress of the Japanese Society for Regenerative Medicine
After decades of research, many regenerative medicine
technologies are in development and approaching commercialization stage, thus leading to the creation of a revenue generating industry.